Head-to-head evidence
dupilumab vs QL2108
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT01949311 · Phase 3 · completed
This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment.
Next expected readout: October 2026 · NCT02612454 (registry estimate)
QL2108
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT06884891 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · QL2108's landscape